Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
45
LXEO Quote, Financials, Valuation and Earnings
Last price:
$10.25
Seasonality move
:
-35.91%
Day range:
$10.02 - $10.70
52-week range:
$1.45 - $10.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.82x
Volume:
522.7K
Avg. volume:
1.3M
1-year change:
51.18%
Market cap:
$340.2M
Revenue:
--
EPS (TTM):
-$2.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
LXEO
Lexeo Therapeutics, Inc.
|
-- | -$0.46 | -- | -61.57% | $19.91 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.96% | -83.59% | $29.79 |
|
ANIX
Anixa Biosciences, Inc.
|
-- | -$0.09 | -100% | -0.45% | $10.00 |
|
GTBP
GT Biopharma, Inc.
|
-- | -- | -- | -- | $8.00 |
|
MBRX
Moleculin Biotech, Inc.
|
-- | -- | -- | -- | $272.33 |
|
PHAT
Phathom Pharmaceuticals, Inc.
|
$47M | -$0.42 | 89.33% | -80.91% | $22.90 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
LXEO
Lexeo Therapeutics, Inc.
|
$10.25 | $19.91 | $340.2M | -- | $0.00 | 0% | -- |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$27.62 | $29.79 | $4.7B | 17.77x | $0.00 | 0% | 4.44x |
|
ANIX
Anixa Biosciences, Inc.
|
$3.20 | $10.00 | $105.3M | -- | $0.00 | 0% | -- |
|
GTBP
GT Biopharma, Inc.
|
$0.83 | $8.00 | $8.9M | -- | $0.00 | 0% | 59.35x |
|
MBRX
Moleculin Biotech, Inc.
|
$3.83 | $272.33 | $7.9M | -- | $0.00 | 0% | -- |
|
PHAT
Phathom Pharmaceuticals, Inc.
|
$17.56 | $22.90 | $1.2B | -- | $0.00 | 0% | 8.62x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
LXEO
Lexeo Therapeutics, Inc.
|
6.54% | 1.568 | 3.84% | 7.11x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ANIX
Anixa Biosciences, Inc.
|
1.27% | 2.400 | 0.21% | 7.76x |
|
GTBP
GT Biopharma, Inc.
|
-- | -0.510 | 4.06% | 1.98x |
|
MBRX
Moleculin Biotech, Inc.
|
-1.47% | 1.294 | 1.49% | 1.18x |
|
PHAT
Phathom Pharmaceuticals, Inc.
|
363.1% | 3.855 | 69.74% | 2.05x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
LXEO
Lexeo Therapeutics, Inc.
|
-$530K | -$21.6M | -80.69% | -86.99% | -- | -$29.8M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ANIX
Anixa Biosciences, Inc.
|
-$9K | -$2.4M | -63.93% | -64.77% | -- | -$1.5M |
|
GTBP
GT Biopharma, Inc.
|
-- | -$3.4M | -626.24% | -626.24% | -- | -$3.7M |
|
MBRX
Moleculin Biotech, Inc.
|
-$21K | -$5.9M | -502.35% | -552.21% | -- | -$7.2M |
|
PHAT
Phathom Pharmaceuticals, Inc.
|
$43.3M | -$15.3M | -115.48% | -- | -30.85% | -$14.1M |
Lexeo Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns LXEO or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of 25.76%. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About LXEO or ACAD?
Lexeo Therapeutics, Inc. has a consensus price target of $19.91, signalling upside risk potential of 94.24%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.79 which suggests that it could grow by 7.86%. Given that Lexeo Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Lexeo Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.9 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is LXEO or ACAD More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock LXEO or ACAD?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or ACAD?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Lexeo Therapeutics, Inc.'s net income of -$20.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus 4.44x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M ACADACADIA Pharmaceuticals, Inc.4.44x 17.77x $278.6M $71.8M
-
Which has Higher Returns LXEO or ANIX?
Anixa Biosciences, Inc. has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of --. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat Anixa Biosciences, Inc.'s return on equity of -64.77%.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M ANIXAnixa Biosciences, Inc.-- -$0.07 $15.6M -
What do Analysts Say About LXEO or ANIX?
Lexeo Therapeutics, Inc. has a consensus price target of $19.91, signalling upside risk potential of 94.24%. On the other hand Anixa Biosciences, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 212.5%. Given that Anixa Biosciences, Inc. has higher upside potential than Lexeo Therapeutics, Inc., analysts believe Anixa Biosciences, Inc. is more attractive than Lexeo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.9 0 0 ANIXAnixa Biosciences, Inc.3 0 0 -
Is LXEO or ANIX More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Anixa Biosciences, Inc. has a beta of 0.488, suggesting its less volatile than the S&P 500 by 51.221%.
-
Which is a Better Dividend Stock LXEO or ANIX?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anixa Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. Anixa Biosciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or ANIX?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than Anixa Biosciences, Inc. quarterly revenues of --. Lexeo Therapeutics, Inc.'s net income of -$20.3M is lower than Anixa Biosciences, Inc.'s net income of -$2.3M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while Anixa Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus -- for Anixa Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M ANIXAnixa Biosciences, Inc.-- -- -- -$2.3M
-
Which has Higher Returns LXEO or GTBP?
GT Biopharma, Inc. has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of --. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat GT Biopharma, Inc.'s return on equity of -626.24%.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M GTBPGT Biopharma, Inc.-- -$0.83 $3M -
What do Analysts Say About LXEO or GTBP?
Lexeo Therapeutics, Inc. has a consensus price target of $19.91, signalling upside risk potential of 94.24%. On the other hand GT Biopharma, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 861.08%. Given that GT Biopharma, Inc. has higher upside potential than Lexeo Therapeutics, Inc., analysts believe GT Biopharma, Inc. is more attractive than Lexeo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.9 0 0 GTBPGT Biopharma, Inc.1 0 0 -
Is LXEO or GTBP More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison GT Biopharma, Inc. has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.367%.
-
Which is a Better Dividend Stock LXEO or GTBP?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GT Biopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. GT Biopharma, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or GTBP?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than GT Biopharma, Inc. quarterly revenues of --. Lexeo Therapeutics, Inc.'s net income of -$20.3M is lower than GT Biopharma, Inc.'s net income of -$3.1M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while GT Biopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus 59.35x for GT Biopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M GTBPGT Biopharma, Inc.59.35x -- -- -$3.1M
-
Which has Higher Returns LXEO or MBRX?
Moleculin Biotech, Inc. has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of --. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat Moleculin Biotech, Inc.'s return on equity of -552.21%.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M MBRXMoleculin Biotech, Inc.-- -$17.02 -$26.5M -
What do Analysts Say About LXEO or MBRX?
Lexeo Therapeutics, Inc. has a consensus price target of $19.91, signalling upside risk potential of 94.24%. On the other hand Moleculin Biotech, Inc. has an analysts' consensus of $272.33 which suggests that it could grow by 7010.53%. Given that Moleculin Biotech, Inc. has higher upside potential than Lexeo Therapeutics, Inc., analysts believe Moleculin Biotech, Inc. is more attractive than Lexeo Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.9 0 0 MBRXMoleculin Biotech, Inc.2 0 0 -
Is LXEO or MBRX More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Moleculin Biotech, Inc. has a beta of 1.582, suggesting its more volatile than the S&P 500 by 58.192%.
-
Which is a Better Dividend Stock LXEO or MBRX?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moleculin Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. Moleculin Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or MBRX?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than Moleculin Biotech, Inc. quarterly revenues of --. Lexeo Therapeutics, Inc.'s net income of -$20.3M is higher than Moleculin Biotech, Inc.'s net income of -$25.4M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while Moleculin Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus -- for Moleculin Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M MBRXMoleculin Biotech, Inc.-- -- -- -$25.4M
-
Which has Higher Returns LXEO or PHAT?
Phathom Pharmaceuticals, Inc. has a net margin of -- compared to Lexeo Therapeutics, Inc.'s net margin of -60.55%. Lexeo Therapeutics, Inc.'s return on equity of -86.99% beat Phathom Pharmaceuticals, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital LXEOLexeo Therapeutics, Inc.-- -$0.33 $129.3M PHATPhathom Pharmaceuticals, Inc.87.5% -$0.41 $160.6M -
What do Analysts Say About LXEO or PHAT?
Lexeo Therapeutics, Inc. has a consensus price target of $19.91, signalling upside risk potential of 94.24%. On the other hand Phathom Pharmaceuticals, Inc. has an analysts' consensus of $22.90 which suggests that it could grow by 30.41%. Given that Lexeo Therapeutics, Inc. has higher upside potential than Phathom Pharmaceuticals, Inc., analysts believe Lexeo Therapeutics, Inc. is more attractive than Phathom Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings LXEOLexeo Therapeutics, Inc.9 0 0 PHATPhathom Pharmaceuticals, Inc.8 2 0 -
Is LXEO or PHAT More Risky?
Lexeo Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Phathom Pharmaceuticals, Inc. has a beta of 0.432, suggesting its less volatile than the S&P 500 by 56.844%.
-
Which is a Better Dividend Stock LXEO or PHAT?
Lexeo Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Phathom Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lexeo Therapeutics, Inc. pays -- of its earnings as a dividend. Phathom Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios LXEO or PHAT?
Lexeo Therapeutics, Inc. quarterly revenues are --, which are smaller than Phathom Pharmaceuticals, Inc. quarterly revenues of $49.5M. Lexeo Therapeutics, Inc.'s net income of -$20.3M is higher than Phathom Pharmaceuticals, Inc.'s net income of -$30M. Notably, Lexeo Therapeutics, Inc.'s price-to-earnings ratio is -- while Phathom Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lexeo Therapeutics, Inc. is -- versus 8.62x for Phathom Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income LXEOLexeo Therapeutics, Inc.-- -- -- -$20.3M PHATPhathom Pharmaceuticals, Inc.8.62x -- $49.5M -$30M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
